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Abstract
Background: The HIV-1 Rev regulatory protein binds as an oligomeric complex to viral RNA
mediating nuclear export of incompletely spliced and non-spliced viral mRNAs encoding the viral
structural proteins. However, the biological significance of the obligatory complex formation of Rev
upon the viral RNA is unclear.
Results: The activity of various fusion proteins based on the negative oligomerization-defect Rev
mutant M4 was tested using Rev dependent reporter constructs. An artificial M4 mutant dimer and
an M4 mutant containing an extra basic domain from the HTLV-I Rex protein exhibited nearly full
activity when compared to wild type Rev.
Conclusion: Rev dimerization appears to be required to expose free basic domains whilst the Rev
oligomeric complex remains bound to viral RNA via other basic domains.
Background
The cytoplasmic expression of unspliced and incom-
pletely spliced HIV-1 mRNAs encoding the HIV-1 struc-
tural proteins and enzymes is dependent upon the Rev
protein [1]. Rev-dependent mRNAs are characterized by
two types of cis-acting sequences, a single Rev response
element (RRE) [2,3] and several cis-acting repressive
sequences (CRS) [4-6]. These sequences are removed in
the completely spliced HIV-mRNAs, which therefore do
not require Rev for cytoplasmic appearance and transla-
tion. The Rev protein, encoded by the completely spliced
HIV-1 mRNA, is a nucleocytoplasmic shuttle protein that
following nuclear import binds to and exports the RRE-
containing RNAs to the cytoplasm [7,8]. Genetic studies
of the 116 residue Rev protein have defined several func-
tional domains; including a basic domain (aa 35–50) that
specifies nuclear and nucleolar localization of Rev (NLS/
NOS) in addition to specific binding of Rev to RRE [3,9-
11]. An other essential domain (aa 75–84) signals active
nuclear export of Rev (NES) [8,12-14]. The Rev basic
domain binds with high affinity to a site within the stem-
loop IIB of the RRE and also to other sites after or upon
oligomerization [15]. This binding of oligomeric Rev to
target RNA is important for Rev function [16]. It is, how-
ever, not clear if Rev binds as a pre-formed complex or if
oligomerization occurs after binding of the first monomer
to the IIB sequence. The binding of monomeric Rev to IIB
may induce conformational changes in the RRE secondary
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structure allowing binding of additional Rev molecules
stabilized by protein-protein interactions [17-19]. How-
ever, Rev oligomerization has been shown to occur inde-
pendently of RRE RNA both in vitro [3,20-22] and in vivo
[23-27]. The fact that Rev forms RNA-independent com-
plexes indicates that complex formation may occur before
binding to RNA. Although following binding of the first
oligomeric Rev complex, additional complexes may bind
to other low affinity sites within RRE. Interactions
between the preformed complexes could then be medi-
ated by residues different from those involved in the pri-
mary complex formation. This model could explain the
apparently conflicting reports identifying different regions
in oligomer formation. However, it is now generally
agreed that sequences flanking the basic domain are
involved in oligomer formation [3,20,21,23,25-27]. Of
the regions reported to be essential for oligomerization,
only the region N-terminal to the basic domain was found
to be necessary for oligomer formation in the cytoplasm
[26,28]. One of these mutants (M4) is mutated at residues
23, 25 and 26 [29]. It is not clear whether the M4 muta-
tions directly affect the residues that are involved in the
oligomer formation or if the mutations cause perturba-
tion of the structure and thus affect the ability to form oli-
gomers [30]. In the current study, the M4 mutant was
studied to clarifying why oligomer formation is essential
for Rev activity by assessing the requirements for restora-
tion of the activity of the mutant.
Results
The intracellular localization of Rev and mutants
The intracellular distribution of the M4 and the M4
derived Rev mutants (schematically outlined in figure 1)
were tested by immunofluorescence in the absence or
presence of 5 nM Leptomycin B (LMB) for 6 hours before
fixation [31]. Wild type Rev localization was predomi-
nantly nuclear and nucleolar while the M4 mutant local-
ized mainly to the cytoplasm with a weak nucleolar and
nucleoplasmic staining (Figure 2, panels a and b). The
addition of the three NLS from the large T-antigen
enhanced nuclear import of the M4 mutant (Figure 2,
panel c), whereas the M4-M4 dimer and the NOS-M4,
which both contain two nuclear import signals, mostly
localized to the cytoplasm. The nuclear staining was
somewhat stronger than that of M4 (Figure 2, panels d
and e). Treatment with LMB did not dramatically change
the distribution of the wild type Rev protein (Figure 2,
panel f). Unexpectedly, the LMB treated cells expressing
the M4 mutants showed accumulation in the nucleus sim-
ilarly to Rev, suggesting that the nuclear import of all the
mutants occurred and that the nuclear export of the M4
mutants was mediated by an LMB-dependent pathway
(Figure 2, panels g-j).
Testing Rev activity using reporters encoding the CAT gene 
within an intron
The functional activity of the mutants was tested using the
two reporter plasmids pDM138-RRE and pDM138-6xIIB
(Figure 1B). Figure 3 displays the results of one experi-
ment showing the CAT expression in COS-7 cells co-tran-
fected with the reporter plasmids together with the M4
mutant plasmids and pcrev. The plasmid pctat  was
included as a negative control. Table 1 shows the results
of three or more additional and independent experiments
related to the activity of wild type Rev, the negative con-
trol and to the relative amount of cell lysates in the sam-
ples. As expected, M4 displayed very low activity
compared to the wild type protein (Figure 3A and 3B,
Table 1). The activity of the M4-3xNLS mutant was also
low using the pDM138-RRE reporter plasmid. Some of
the activity was rescued using pDM138-6xIIB but addition
of 3xNLS to Rev also enhanced the relative Rev activity
(Table 1). In contrast to the M4 and M4-3xNLS mutants,
M4-M4 and NOS-M4 were both active in co-transfection
experiments using the Rev dependent pDM138 reporter
plasmids containing RRE or six IIB high affinity binding
sites (Figure 3A and 3B, Table 1).
There are conflicting reports of Rex's ability to rescue RRE
RNA [32,33]. Therefore, cells were co-transfected with the
Rev dependent reporters pDM138-RRE and pDM138-
6xIIB together with a vector encoding Rex. The Rex
dependent reporter pDM138-RxRE was included as a pos-
itive control for Rex activity. Rex dependent CAT expres-
sion was only detected when using pDM138-RxRE
containing the specific Rex responsive element (Figure
3C). This indicated that the Rex-NOS sequence in NOS-
M4 did not bind to IIB in the co-transfection experiments
using pDM138-RRE and pDM138-6xIIB.
Testing Rev activity using a cell line expressing HIV-1 gag 
mRNA including a CRS element
Wild type Rev and the mutants were also tested by trans-
fecting pcrev and the mutant plasmids into the stable cell
line A3.9 expressing a gag mRNA fused to RRE [34]. No
Gag p55 was detected in cells transfected with pcrevM4
and pcrevM4-3xNLS whilst Rev dependent Gag expression
was observed in cells expressing Rev and the two mutants
M4-M4 and NOS-M4 (Figure 4, right panels). However,
compared to the cells transfected with pcrev, the number
of Gag positive cells and the amount of Gag protein
expressed in single cells was clearly less in cells transfected
with pcrevM4-M4 and pcrevNOS-M4 (Figure 4). This
trend was confirmed by western blot analysis of trans-
fected A3.9 cells (not shown). In the A3.9 cells the cyto-
plasmic localization of the M4 mutants was even clearer
than in the COS-7 cells (Figure 4 left panels).Retrovirology 2005, 2:39 http://www.retrovirology.com/content/2/1/39
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A, Schematic diagram of wild type and Rev mutants Figure 1
A, Schematic diagram of wild type and Rev mutants. The location of the M4 mutations are indicated by arrows. The Rev basic 
domain is indicated as Rev-NOS, the three copies of the large T-antigen NLS are indicated as 3xNLS, the Rex overlapping NLS/
NOS signal is shown as Rex-NOS. B, Schematic diagram of the reporter systems. The CAT gene and the 5' and 3' splice sites 
are indicated. The Rev and Rex responsive elements are indicated as RRE and RxRE respectively. The 6 copies of the Rev high 
affinity binding site IIB is indicated as 6xIIB. The Rev dependent gag mRNA with the CRS element fused to the RRE expressed 
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Discussion
The intracellular distribution of M4 was previously found
to be mainly cytoplasmic [14,26]. Since this mutant has
been shown to bind to RRE [3], an alternative explanation
for the loss of function could be that cytoplasmic reten-
tion of M4 resulted in lack of M4 in the nucleus. The
present study was conducted to test this hypothesis by
using a combination of extra nuclear import signals for
the M4 mutant and employing a reporter allowing bind-
ing of six Rev molecules to the RNA. The experiments
using M4-3xNLS showed that neither efficient nuclear
import nor binding of six monomers to intron RNA was
sufficient for restoration of activity. Some of the activity of
M4-3xNLS was rescued when the RRE sequence was
replaced by 6xIIB allowing binding of six molecules to
RNA. Control experiments with pcrev-3xNLS demon-
strated that the addition of 3xNLS also enhanced the rela-
tive activity of Rev using the reporter pDM138-6xIIB
(Table 1). Thus, the extra lysine rich NLS signals may have
improved the nuclear import or increased non-specific
binding to the viral RNA. The M4-M4 mutant comprises
two NES signals whilst NOS-M4 contains only one. Both
mutants were, however, highly active in co-transfection
experiments using the Rev dependent pDM138 reporter
plasmids suggesting that the extra NES signal in M4-M4 is
not responsible for the rescue of Rev activity (Figure 3,
Table 1).
There was no significant difference in activity of wild type
Rev or the NOS-M4 and M4-M4 mutants whether the
reporter contained RRE or six IIB high affinity binding
sites. This is in agreement with previous findings suggest-
ing that the formation of oligomeric complexes on RRE is
mainly dependent on protein-protein interactions and
not so dependent on the RNA sequences specificity out-
side the IIB site [15].
The intracellular steady state localization of the wild type Rev  and mutants is shown in the panels to the left (panels a-e) Figure 2
The intracellular steady state localization of the wild type Rev 
and mutants is shown in the panels to the left (panels a-e). 
The panels to the rights show the nuclear accumulation of 
the wild type and mutant proteins after treatment with 5 nM 
LMB for 6 hours (panels f-j). The anti-Rev Mab 8E7 combined 
with FITC labeled anti-mouse IgG2a (Southern Biotech) was 
used for detection of Rev and the M4 mutants.
Table 1: The relative activity of Rev and M4 mutants
pDM138-RRE Rev 
activity as CAT 
produced (%)
pDM138-6xIIB Rev 
activity as CAT 
produced (%)






Tat (negative control) 0 0
The numbers represent the mean value of three or more independent 
experiments related to the activity of wild type Rev, the negative 
control and the amount of cellular protein.Retrovirology 2005, 2:39 http://www.retrovirology.com/content/2/1/39
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The two mutants M4-M4 and NOS-M4 also activated Gag-
expression in A3.9 cells. Thus, these mutants were also
active in this essentially different reporter system. The
pDM138 plasmids encode mRNAs with the CAT gene
flanked by the HIV-1 splice sites. These splice sites are not
present within the gag mRNA expressed in the A3.9 cell
line. Although the presence of a cis-acting repressor ele-
ment (CRS) requires Rev in trans for expression of the p55
Gag protein [34].
The common feature of NOS-M4 and M4-M4 is the pres-
ence of two functionally similar basic domains. The dimer
included two copies of the Rev basic domain while NOS-
M4 contained one domain from Rev and one from Rex.
The function of the HTLV-I Rex protein is similar to that
of Rev and the basic domains from the two viral proteins
bind to Importin β  during nuclear import [35,36]. It is
therefore likely that the two protein domains interact in a
similar manner with other putative cellular cofactors. Pre-
vious reports have shown that Rex is able to rescue RRE
containing RNA [32,33]. However, the binding site for
Rex was shown to be different from the Rev binding site
IIB [37]. Other studies did not confirm that Rex replaces
Rev in trans-activity assays [38]. The co-transfection exper-
iments in this study showed that Rex was not able to
induce CAT expression from the Rev-dependent pDM138
reporters indicating that the Rex NOS domain did not
bind the IIB or RRE sequences in this context (Figure 3C).
The rescue of activity of the mutants M4-M4 and NOS-M4
could be explained by at least two models. Both mutants
comprise two basic domains with comparable functions.
We found that Rex did not activate CAT expression from
the Rev dependent pDM138 reporters. This indicated that
the NOS-M4 mutant binds to the IIB RNA sequences by
the Rev basic domain leaving the Rex domain free for
other interactions. The previous observation that a pep-
tide corresponding to the basic domain of Rev inhibited
the in vitro splicing of RRE containing mRNAs underscores
the functional importance of this region [39,40]. These
results therefore support the suggestion that the basic
domain participates in events other than binding to
nuclear import factors and target RNA. This implies that at
least one of the functional benefits of oligomer formation
of Rev is that free basic domains can be exposed while the
complex is tethered to RNA via other basic domains. Alter-
natively, the addition of extra sequences may have stabi-
lized the structure of the otherwise unstable monomeric
mutant, suggesting that dimer formation may be essential
for obtaining a stable Rev structure.
Conclusion
The present study showed that the activity of the negative
monomeric M4 mutant was rescued by addition of an
extra basic domain implying that two or more basic
domains must be present within the complexes that bind
to target RNA. This can be important for structural reasons
or for leaving free basic domains for interaction with




The plasmids pcrev-3xNLS and pcrevM4-3xNLS encoding
Rev and the M4 mutant with three C-terminal copies of
the SV40 large T antigen NLS were constructed by ampli-
fying the rev coding region from pcrev and pcrevM4 using
the primer pair catgccatggcaggaaga agcggag / ccgctcgagt-
tctttagttcctgactccaa [1,29]. The PCR products were cloned
into the NcoI-and  XhoI-digested pCMV/myc/nuc vector
(Invitrogen). The plasmid pcrevM4-M4 encodes an artifi-
cial M4 dimer with the monomers connected by a glycine
Functional analysis of wild type Rev and M4 mutants by western blot analysis of COS-7 cells co-transfected with the Rev  dependent reporter plasmids pDM138-RRE (A, C), pDM138-6xIIB (B, C) or the Rex dependent reporter plasmid pDM138- RxRE (C) together with the plasmids indicated above the lanes Figure 3
Functional analysis of wild type Rev and M4 mutants by western blot analysis of COS-7 cells co-transfected with the Rev 
dependent reporter plasmids pDM138-RRE (A, C), pDM138-6xIIB (B, C) or the Rex dependent reporter plasmid pDM138-
RxRE (C) together with the plasmids indicated above the lanes. The CAT protein was detected by polyclonal anti-CAT anti-
bodies (Sigma) combined with HRP-labeled anti-rabbit Ig (Amersham) and developed using ECL. The lane numbers are indi-
cated below.Retrovirology 2005, 2:39 http://www.retrovirology.com/content/2/1/39
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rich linker. The rev  coding region from pcrevM4 was
amplified using the primer pairs tcgaagctagtcgacatctcctatg
/ cggggtaccgcctccttctttagctcc (PCR A) and cggggtaccggaat-
ggcaggaagaagc / ctccagttggtagagagagcag (PCR B). The
reverse primer in PCR B binds 70 nucleotides downstream
from an XhoI site present in pcrevM4. The PCR product A
was digested with SalI and KpnI while PCR B was digested
with KpnI and XhoI. The two PCR products were ligated
together into the SalI and XhoI digested pcrev vector. The
NOS-M4 mutant contained the overlapping NLS/NOS
from the HTLV-1 Rex protein fused to the N-terminal. The
plasmid was constructed by inserting the NcoI-and XhoI
digested fragment from pcrevM4-3xNLS into the NcoI-and
XhoI digested pCMV/myc/cyto vector (Invitrogen), and
inserting an NcoI flanked oligo encoding the overlapping
NLS/NOS signal from the HTLV-1 Rex protein into the
NcoI digested pcrevM4-myc vector. An overview of Rev
and the Rev mutants is shown in figure 1A. The rex
sequence was amplified from pcD-Srα  Rex provided by
Dr. Shida and cloned into the pcrev vector after excising
the rev gene [41,42]. The Rev dependent pDM138-RRE
and the Rex dependent pDM138-RxRE reporter plasmids
contain the chloramphenicol acetyltransferase (CAT)
gene and RRE or RxRE elements respectively within HIV
intron sequences flanked by the 5' and 3' splice sites from
the env gene [43,44]. In the plasmid pDM138-6xIIB the
RRE sequence was replaced by six repeats of the IIB high
affinity site for Rev binding allowing binding of six mon-
omers [40]. The Rev dependent reporter plasmids are
schematically shown in figure 1B.
Transfections and cell lines
The A3.9 cell line stably expressing the gag mRNA fused to
the RRE sequence was provided by M.L. Hammarskjöld
and D. Rekosh. Transfection of A3.9 cells and COS-7 cells
in 35 mm wells were carried out using Lipofectamine Rea-
gent 2000 (GIBCO BRL Life Technologies) according to
the manufacturer's recommendations. One coverslip was
added to each 35 mm well and CAT and Rev expression by
western blot and immunofluorescence respectively were
analysed in parallel. Each 35 mm well was transfected
with 1 µg of the pDM138 reporter plasmids. The amount
of rev plasmid DNA varied from 0.2 – 2 µg in order to
obtain the same amount of Rev or mutant protein
expressed in the cells. The Rev protein levels were esti-
mated by immunofluorescence. Of the control plasmids
pcrex and pctat, 4 µg and 1 µg respectively were added and
the expression was confirmed by immunofluorescence.
Immunofluorescence and western blot analysis
The cells were fixed or harvested 24 or 48 h post transfec-
tion for analysis by immunofluorescence and western blot
respectively as previously described [28]. The immunoflu-
orescence labeled cells were examined and the images
were captured using the Leica DM RXA confocal scanning
Functional analysis of wild type Rev and M4 mutants by single  cell analysis of transfected methanol fixed A3.9 cells express- ing Rev-dependent gag mRNA Figure 4
Functional analysis of wild type Rev and M4 mutants by single 
cell analysis of transfected methanol fixed A3.9 cells express-
ing Rev-dependent gag mRNA. The panels to the left show 
expression of Rev and the mutants detected by the anti-Rev 
Mab 8E7. The panels to the right show Gag expression in the 
same cells. Gag p55 was detected using the anti-p24 Mab.Retrovirology 2005, 2:39 http://www.retrovirology.com/content/2/1/39
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microscope with Leica PowerScan software attached. The
figures were created using the program Adobe Photoshop
version 3.0. The bands of the western blot analysis were
scanned using an Agfa Snapscan 600 flatbed scanner and
quantified using FUJIFILM LAS-1000 ProVer. 2.02 and
Image Gauge V.3.45. The CAT bands were related to the
activity of Rev set to 100 %, the negative control set to 0
% and the intensity of cellular bands representing the
amount of cell lysate in the sample. Calculations were not
performed when cellular background bands were not vis-
ible as in the experiments shown in figure 3.
Antibodies
The Rev proteins were detected by the anti-Rev Mab 8E7
[45].
Tat and Rex were detected using the Mabs 1D9 and 1F8
respectively (not shown) [42,46]. The anti-Gag p24 Mab
for detection of full length Gag p55 expressed in A3.9 cells
was supplied by H.C. Holmes, Medical Research Council,
London, UK [47]. The polyclonal rabbit antibody for
detection of the CAT protein was from Sigma.
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